Immix Biopharma, Inc. (NASDAQ:IMMX) Stock Now Rated “Moderate Buy” by Wall Street Brokerages

Immix Biopharma, Inc. (NASDAQ:IMMX – Get Free Report) has earned an average recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating and eight have issued a buy rating on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $24.14.

IMMX has been the subject of several recent research reports. Needham & Company LLC increased their price target on Immix Biopharma from $21.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, September 29th. Citigroup reiterated a “market outperform” rating on shares of Immix Biopharma in a research report on Wednesday, September 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immix Biopharma in a research note on Thursday, October 15th. Morgan Stanley boosted their price objective on shares of Immix Biopharma from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Wednesday. Finally, Mizuho cut their price objective on shares of Immix Biopharma from $23.00 to $22.00 and set an “outperform” rating for the company in a research report on Wednesday.

Read Our Latest Stock Analysis on IMMX

Key Headlines Impacting Immix Biopharma

Investors following IMMX have been watching these headlines:

  • Positive Sentiment: HC Wainwright continues to rate IMMX “Buy” with a $27 target. It also raised its estimates for Q1 and Q2 2027 and slightly improved its Q4 2026 forecast, partly offsetting the reductions to other periods. HC Wainwright analyst coverage
  • Neutral Sentiment: Mizuho trimmed its target to $22 from $23 but retained an “Outperform” rating, keeping its outlook positive while signaling a modestly lower valuation expectation. Mizuho ratings
  • Negative Sentiment: HC Wainwright cut its FY2027 loss-per-share estimate to $0.86 from $0.20, with notable reductions to Q3 and Q4 2027 forecasts. The revised estimates suggest larger expected losses and temper the positive impact of the firm’s Buy rating and $27 target. HC Wainwright analyst coverage

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in IMMX. Aquatic Capital Management LLC purchased a new position in Immix Biopharma during the third quarter worth about $771,000. Mathes Company Inc. lifted its position in Immix Biopharma by 23.5% in the third quarter. Mathes Company Inc. now owns 13,150 shares of the company’s stock valued at $137,000 after purchasing an additional 2,500 shares during the period. Marshall Wace LLP lifted its position in Immix Biopharma by 3.3% in the third quarter. Marshall Wace LLP now owns 1,854,215 shares of the company’s stock valued at $19,284,000 after purchasing an additional 59,307 shares during the period. Blue Owl Capital Holdings LP boosted its holdings in Immix Biopharma by 37.6% in the 3rd quarter. Blue Owl Capital Holdings LP now owns 602,047 shares of the company’s stock valued at $6,264,000 after purchasing an additional 164,495 shares in the last quarter. Finally, Voya Investment Management LLC purchased a new stake in Immix Biopharma in the 3rd quarter valued at approximately $116,000. 11.26% of the stock is currently owned by institutional investors and hedge funds.

Immix Biopharma Stock Down 1.0%

IMMX opened at $7.04 on Friday. Immix Biopharma has a 52 week low of $3.78 and a 52 week high of $15.10. The business has a 50 day moving average price of $9.35 and a two-hundred day moving average price of $9.61. The company has a market cap of $590.02 million, a PE ratio of -8.48 and a beta of 0.29.

Immix Biopharma (NASDAQ:IMMX – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.19) earnings per share for the quarter, meeting the consensus estimate of ($0.19). As a group, sell-side analysts expect that Immix Biopharma will post -0.75 EPS for the current fiscal year.

About Immix Biopharma

(Get Free Report)

Immix Biopharma is a clinical-stage biopharmaceutical company developing cell therapies for serious diseases, with a focus on relapsed or refractory AL amyloidosis, a rare condition in which abnormal proteins build up in organs and tissues. The company’s lead candidate, NXC-201, is an investigational CAR T-cell therapy designed to target BCMA, a protein found on certain plasma cells. It is being studied in clinical trials and has not been approved for commercial use. Immix Biopharma is based in the United States and is led by Chief Executive Officer Ilya Rachman.

Featured Stories

Analyst Recommendations for Immix Biopharma (NASDAQ:IMMX)

Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.